Aid by Sector
South Sudan Health Pooled Fund Phase III
UK - Foreign, Commonwealth Development Office (FCDO)
To provide a government led effective health system that will deliver improved access to quality health services across seven states in South Sudan with a specific focus on reducing maternal and child mortality. The Health Pooled Fund (HPF3) will reduce maternal and under-five mortality rates in South Sudan, through (i) the delivery of a basic package of health and nutrition services; (ii) promoting community engagement in health as a public good and (iii) supporting local health systems stabilisation.
LAFIYA -UK Support for Health in Nigeria
UK - Foreign, Commonwealth Development Office (FCDO)
To save lives, reduce suffering and improve economic prospects for the poorest and most vulnerable in Nigeria through: i. Encouraging Government of Nigeria to increase resources invested in health (through advocacy, community accountability; and data to inform government prioritisation using a “delivery” approach, as used successfully in Pakistan) ii. Improving effectiveness and efficiency of public and private basic health services (through innovative financing mechanisms, strengthening health systems and working with private sector to deliver affordable health services for the poorest populations) iii. Reducing total fertility rate (through addressing social norms, demographic impact analysis, and support to family planning commodities and services).
Essential Services for Maternal and Child Health [Services Essentiels de Santé Maternelle et Infantile en RDC (SEMI)]
UK - Foreign, Commonwealth Development Office (FCDO)
To support essential maternal, child and infant health services to end preventable deaths in one of the poorest provinces in DRC and strengthen the health system at national and provincial level.
Umoyo Wathu Health System Strengthening Programme
UK - Foreign, Commonwealth Development Office (FCDO)
To reduce rates and inequalities in maternal, under-5 and new-born deaths; as well as reduce stunting in under-5s, by strengthening the quality and coverage of a package of essential health services through lower level district administration. The programme will increase the provision and uptake of quality, highly cost effective life-saving primary healthcare services provided free at the point of use, and so better protect the most vulnerable against the financial consequences of ill health. By 2028, the programme will contribute to reducing maternal mortality from 439 to 350 per 100,000 births; neonatal mortality from 27 to 22 per 1,000 live births; child mortality from 64 to 48 per 1,000 live births; stunting in children under five years of age reduced from 37% to 31%; and impact of communicable disease outbreaks and epidemics.
Nepal Health Sector Programme III
UK - Foreign, Commonwealth Development Office (FCDO)
To improve the health of women, children, the poor and socially excluded in Nepal, including by restoring health services in areas affected by the 2015 earthquake, and improving the quality and governance of health services nationwide.
Responding to the needs of Women and Children in Yemen 301140
UK - Foreign, Commonwealth Development Office (FCDO)
This programme will address the devastating impact the conflict in Yemen is having on women and children, particularly the most marginalised. It will provide access to life-saving integrated health, nutrition, water, sanitation and hygiene (WASH) and protection services. This approach responds directly to two key UK humanitarian aims in Yemen: preventing famine and ensuring respect for International Humanitarian Law.
Better Health in Bangladesh (BHB) Programme
UK - Foreign, Commonwealth Development Office (FCDO)
To deliver more and higher quality services, contributing to better health through technical assistance and policy engagement. The programme is contributing to ending preventable deaths of mothers, babies and children, tackling antimicrobial resistance and addressing climate change impact on health.
Scaling up Family Planning in Tanzania
UK - Foreign, Commonwealth Development Office (FCDO)
This is a national programme to scale up access to family planning across Tanzania. Specific activities will include: • Outreach work in rural and urban areas as well as in Tanzania’s refugee camps and host communities. • Specific work to improve access to family planning as well as sexual and reproductive health information to youth, people with disabilities as well as services for victims of sexual violence. • Procure family planning commodities, strengthen the supply chain, and train of public health providers
Better Lives for Somali Women and Children
UK - Foreign, Commonwealth Development Office (FCDO)
To achieve UK's manifesto commitment of reducing preventable deaths, the Better Lives for Somali Women and Children will continue to respond to the health and nutrition needs of the Somali people. There will be a continued focus on delivering an essential package of health services. The programme will strengthen the Somali Health Authorities oversight of service provision, which will in turn promote local accountability and allow them increasingly to respond to the needs of their populations. This programme approach aims to support long term sustainability and state building that is part of the wider strategic agenda. There will also be a climate change mitigation component (ICF) within the programme.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in AMR Diagnostic Tools with FIND
UK - Department of Health and Social Care (DHSC)
FIND is a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. UK Department of Health and Social Care (DHSC) funding through the Global AMR Innovation Fund (GAMRIF) will support FIND’s work to enhance the impact of diagnostic tools for antimicrobial resistance (AMR), to support improved AMR surveillance and antibiotic stewardship. This work has two areas of focus: 1) to develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access of data; and 2) to develop a new diagnostic technologies for drug-resistant gonorrhea, which will enable improved diagnosis and therefore use of new antibiotics. Projects funded through GAMRIF will primarily benefit people in low- and middle-income countries, where the burden of drug-resistant infection is greater.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with BactiVac
UK - Department of Health and Social Care (DHSC)
Vaccine Innovation with BactiVac is a partnership between the UK government and the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for AMR in humans and animals. The UK government has invested up to £1 million over one year into BactiVac, which is one of 5 networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research & Development. This is co-funded by the Medical Research Council (MRC) and Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships, and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for antimicrobial resistance (AMR) for the benefit of people in low- and middle-income countries (LMICs). Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
UK Public Health Rapid Support Team - Rapid investigation and response
UK - Department of Health and Social Care (DHSC)
"Created in 2016, the UK-PHRST is the primary arm of Her Majesty’s Government to provide and coordinate the UK’s public health response to outbreaks in LMICs. The UK-PHRST is a unique collaboration between Public Health England and the London School of Hygiene and Tropical Medicine with input from a number of academic partners. The UK-PHRST’s remit covers outbreak response, research, and capacity building, as components of its integrated triple mandate: • Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance (ODA), with the aim of stopping a public health threat from becoming a broader health emergency • Conduct research to generate an evidence base for best practice in epidemic preparedness and response • Build capacity for improved and rapid national response to disease outbreaks in LMICs and contribute to supporting implementation of IHR at the request of national governments or international stakeholders such as WHO. The UK-PHRST rapidly deploys a standing team of multidisciplinary public health professionals and researchers as required in countries that are a priority for the UK’s ODA programme. The UK-PHRST full-time Core Deployable Team consists of specialists in epidemiology, laboratory microbiology, infection prevention and control, clinical case management and clinical research, social science, data management and logistical support who are available to deploy within 48 of an approved request. Reservists and Field Epidemiology Training Programme (FETP) Fellows complement this team, providing surge capacity and specialist expertise when needed. The UK-PHRST is financed through UK Official Development Assistance (ODA) funding through the Department of Health and Social Care. The UK-PHRST Director is the accountable person to the UK Government, through PHE, for delivery of the UK-PHRST objectives." "The UK-Public Health Rapid Support Team is a key international partner in epidemic disease response. We partner with low- and-middle income countries to respond to infectious disease outbreaks before they can develop into global health emergencies. We work closely with international organisations, partner country governments and non-governmental organisations to: - Rapidly investigate and respond to disease outbreaks at their source in LMICs eligible for UK Official Development Assistance, with the aim of stopping a public health threat from becoming a broader health emergency - Conduct research to generate an evidence base for best practice in epidemic preparedness and response - Strengthen capacity for improved national response to disease outbreaks in LMICs We are an innovative partnership between the UK Health Security Agency and the London School of Hygiene & Tropical Medicine, funded with UK aid by the UK Department of Health and Social Care." The UK Public Health Rapid Support Team (UK -PHRST) has the following main objectives: 1) Within ODA eligible countries to support the rapid investigation and response to disease outbreaks at source, with the aim of stopping a public health threat becoming a health emergency. 2) Conduct rigorous research to aid epidemic preparedness and response and improve future response. 3) Generate an evidence base for best practice in disease outbreak interventions within ODA eligible countries. 4) Train a cadre of public health reservists for the UK -PHRST who can be rapidly deployed to respond to disease outbreaks. 5) Build capacity in-country for an improved and rapid national response to disease outbreaks and contribute to supporting implementation of the International Health Regulations (IHR).
UK Vaccine Network - BactiVac Network
UK - Department of Health and Social Care (DHSC)
The BactiVac Network aims to accelerate the development of vaccines against bacterial infections aimed at reducing antimicrobial use in humans and animals, relevant to low- and middle-income countries (LMICs). An investment of up to £1,400,000 will fund projects in two rounds of funding that support the development of vaccines that can prevent and/or minimise the emergence and transmission of antimicrobial resistance (AMR). Partnerships of at least two organisations are a requirement of funding, with at least one partner based in the UK, and partnerships with LMIC researchers are prioritised. This grant will directly benefit people in LMICs, both from the research and the established partnerships which will then be able to apply for further substantive follow-on funding in the field. The primary aim of the funding is to support new, diverse research projects to gain preliminary data and encourage establishment of new research partnerships and allow these collaborations to build a track record, which will allow them to attain further funding. It is expected that some of these projects will fail, yet the dissemination of both positive and negative research outcomes is valuable and is expected. Funding will also support other Network activities which promote collaboration across the membership, particularly for members based in LMICs.
UK Vaccine Network - Vaccine Manufacturing Research Hubs Competition 2
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. The UK Vaccine Network has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is collaborating with EPSRC (a nondepartmental public body principally funded through the Science Budget by the Department of Science, Innovation and Technology) in running the Vaccine Manufacturing Research Hubs competition. EPSRC has considerable expertise in running competitions in this nature. The Vaccine Manufacturing Research Hubs competition will be open to all eligible research organisations that can demonstrate that their work would contribute towards Vaccine Manufacturing Research. Successful projects will be awarded a research grant from EPSRC, mostly funded by DHSC.
UK Vaccine Network - UK Health Security Agency
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. The Department of Health and Social Care (DHSC) is making up to £3,100,000 available to the UK Health Security Agency (UKHSA) under the provisions of the International Development Act of 2002 to deliver a programme of seven projects that will advance vaccine development for diseases of epidemic potential for the benefit of people in low- and middle-income countries (LMICs). The programme will be wholly funded by DHSC through UK aid. The seven projects are: 1. CL4 Live Virus Neutralisation Tests; 2. Development of PNA Capability for Priority Pathogens; 3. Multiplex pAn-Virus Inhibition (MAVI) assays; 4. Preclinical model expansion for the assessment of cross-protective vaccines candidates against henipaviruses; 5. Development of GMP LassaVacc: Progression towards clinical trials; 6. Development of an X-ray inactivated whole virus vaccine for Zika and efficacy testing in an established rodent model; and 7. Advancement of a cost-effective MVA based Hantavirus vaccine (HantaVacc).
UK Vaccine Network - Vaccines for epidemic diseases: readiness for clinical development and regulatory submission competition
UK - Department of Health and Social Care (DHSC)
The Project is a Small Business Research Initiative (SBRI), Official Development Assistance (ODA) competition funded by the Department of Health and Social Care (DHSC). The aim of the competition is to further invest in vaccines and vaccine technologies to address the 12 priority diseases (including Disease X) identified by the UK Vaccine Network. Proposals can address any part of the pre-clinical, non-clinical, manufacturing, or clinical pathway, within a 1-year time frame, making technology ready to be progressed further along the developmental pathway. This is a managed programme on behalf of DHSC. UKRI-Innovate UK are providing a fully managed end to end service. The call goes live on 4th October 2021. The SBRI contracts are required to be in place and live by 31 March 2022. Beneficiary Projects funded through this competition are required to primarily benefit ODA eligible countries, as per ODA policy.
UK Vaccine Network - Vaccine development for diseases with epidemic potential
UK - Department of Health and Social Care (DHSC)
The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. DHSC is engaging Innovate UK (an Executive Non-Departmental Public Body established by the Higher Education and Research Act 2017) to run the Vaccine development for diseases with epidemic potential competition. Innovate UK are responsible for the delivery and management of this work on behalf of DHSC. DHSC is making up to £25,000,000 (twenty-five million pounds) available to Innovate UK under the provisions of the International Development Act of 2002 to run the Vaccine development for diseases with epidemic potential competition and fund the Successful Project(s).
UK Vaccine Network - Global Health Security and Medicines and Healthcare Products Regulatory Agency
UK - Department of Health and Social Care (DHSC)
The UK Department of Health and Social Care (DHSC) is collaborating with the Medicines and Healthcare products Regulatory Agency (MHRA) to deliver a programme of work consisting of two Work Packages, one with UKVN and the other with the Global AMR Innovation Fund (GAMRIF). The Prime Minister established the UK Vaccine Network (UKVN) in June 2015 to ensure that the UK was at the forefront of the fight against future disease outbreaks. UKVN has identified a range of human diseases with epidemic potential for which the development of vaccines is a priority. GAMRIF was established in 2016 in response to the Review on Antimicrobial Resistance chaired by Lord Jim O’Neill. It is a One Health UK aid fund that supports research and development (R&D) around the world to reduce the threat of antimicrobial resistance (AMR) in humans, animals and the environment by progressing therapeutics, preventatives and diagnostics along the pipeline for the benefit of people in low- and middle-income countries (LMICs). DHSC is making up to £2,700,000 available to the Partners under the provisions of the International Development Act of 2002 to manage and deliver the two Work Packages. Up to £1,000,000 of this will be for Work Package 1 (UKVN) and up to £1,700,000 for Work Package 2 (GAMRIF). The UKVN Work Package Supporting epidemic and pandemic preparedness by expanding the portfolio of research reagents for emerging viruses. Summary: Simple and timely access to high quality research reagents would accelerate the development of vaccines against emerging infectious diseases, particularly for scientists from low and middle-income countries (LMICs), which are frequently the worst affected. To meet this global need, we propose to expand the Centre for AIDS Reagents (CFAR) to become the Centre for Infectious Disease Reagents (CIDR). The existing CFAR repository at the Medicine and Healthcare products Regulatory Agency (MHRA), has successfully been providing a sustained research reagent resource to the scientific community since 1989, supplying more than 8500 vials of reagents to hundreds of organisations globally, in the past 10 years. Using our existing network and successful operating model, we would, with the expansion of scope for CIDR: Encourage leading laboratories to deposit state of the art research materials to our repository; Produce new reagents, primarily recombinant proteins and pseudotyped viruses; Commission new reagents from collaborators, including peptides and monoclonal antibodies. These materials will be prioritized to organisations in LMICs which will benefit from free of charge access. Our proven track record for collaboration, production and distribution of research reagents assures an ongoing legacy resource for research on emerging pathogens.
Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment
UK - Department of Health and Social Care (DHSC)
A grant to the Centre for Cellular and Mollecular Platforms (C-CAMP) to deliver a national and international call for application (‘AMR Challenge’) to identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of low- and middle-income countries(LMICs). The Challenge will be specific for AMR in the Environment and will be executed independently as curated and designed by GAMRIF and C-CAMP. However, through the broader umbrella of the India AMR Innovation Hub (Hub), anchored by C-CAMP, the larger stakeholder network may be leveraged for advancing the innovations identified through the Challenge.
Global Antimicrobial Resistance Innovation Fund (GAMRIF) - InnoVet AMR: Innovative Veterinary Solutions for AMR with IDRC
UK - Department of Health and Social Care (DHSC)
InnoVet-AMR is a partnership between DHSC and the International Development Research Centre (IDRC) aimed at reducing the emerging risk that antimicrobial resistance (AMR) in animals poses to global health and food security. InnoVet-AMR will fund research to develop new animal vaccines and other innovations to fight AMR in livestock (swine and poultry) and aquaculture production, particularly in low- and middle-income countries (LMICs). Through InnoVet-AMR, IDRC and DHSC aim to achieve two main objectives: (1) support research that will identify innovative veterinary solutions, including vaccines and alternative solutions, to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs; (2) build effective partnerships to better coordinate discovery, development and sustainable delivery of affordable innovative veterinary solutions to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs. Projects funded through the Global AMR Innovation Fund (GAMRIF) will primarily benefit people in LMICs, where the burden of drug-resistant infection is greater.
Advanced filters
To search for Programmes in a specific time period, please enter the start and end dates.